FNP Contraception Counseling Practice Questions

It is normal for adolescents to experience irregular menstrual cycles during the first one to two years following menarche due to immature hypothalamic-pituitary-ovarian axis functioning, resulting in anovulatory cycles. For a 13-year-old female whose menarche occurred six months ago, the most appropriate action is to explain that irregular cycles are expected. Prescribing oral contraceptives (A) is unnecessary for normal physiologic irregularity. Ordering an ultrasound (C) or referring to endocrinology (D) is premature and unwarranted unless the irregularity persists beyond two years or is accompanied by signs of hyperandrogenism.

The patient is experiencing physiologic leukorrhea, a normal increase in clear, non-irritating vaginal discharge that often occurs mid-cycle due to estrogen peaks. The vaginal pH is appropriately acidic at 4.0. The wet prep confirms a healthy vaginal ecosystem, showing mature squamous epithelial cells with distinct cell margins, abundant lactobacilli, and minimal white blood cells. Option D is the correct assessment. Option A is incorrect; bacterial vaginosis would present with an elevated pH (>4.5) and clue cells with obscured borders. Option B is incorrect; candidal vaginitis would present with pruritus, thick discharge, and pseudohyphae on a KOH prep. Option C is incorrect; trichomonas infection would present with an elevated pH, inflammation, and motile organisms. Reassuring the patient about normal physiologic changes is an essential aspect of young adult reproductive care.

This patient is experiencing genitourinary syndrome of menopause, characterized by severe dyspareunia and dryness, but she explicitly reports having no hot flashes. The standard of care for isolated vaginal symptoms is local vaginal estrogen, which provides targeted relief without significant systemic absorption. Therefore, Option C is the most appropriate plan of care. Because systemic absorption is minimal with low-dose vaginal preparations, a concomitant progestin is generally not required even with an intact uterus. Options A and B are incorrect because systemic oral or transdermal hormone therapy exposes the patient to unnecessary systemic risks (such as venous thromboembolism) when her symptoms are purely localized. Option D is incorrect because while ospemifene is an oral selective estrogen receptor modulator approved for dyspareunia, local topical estrogen is considered the first-line, most direct approach with fewer systemic side effects.

Migraine with aura (visual changes) is a Category 4 contraindication for any estrogen-containing contraceptive due to an unacceptable increase in the risk of ischemic stroke. A levonorgestrel intrauterine device is a progestin-only method that is highly effective, safe for adolescents, and does not carry this cardiovascular risk. Option A is incorrect because the combined oral contraceptive pill contains estrogen, making it unsafe for this patient. Option B is incorrect because the contraceptive vaginal ring also contains ethinyl estradiol and carries the same stroke risk. Option D is incorrect because the transdermal patch delivers systemic estrogen, which is strictly contraindicated. Progestin-only methods, including the levonorgestrel IUD, etonogestrel implant, or progestin-only pills, are the evidence-based choices for patients with migraine with aura.

The copper intrauterine device is the most effective method of emergency contraception and can be inserted up to five days after unprotected intercourse. It perfectly matches her request for ongoing, highly effective contraception that does not require daily adherence, and its efficacy is not diminished by her elevated body mass index. Option A is suboptimal because oral levonorgestrel has decreased efficacy in patients with a BMI over 30, and it delays the initiation of her long-term method. Option B is incorrect because starting hormonal contraception on the same day as ulipristal acetate can reduce the effectiveness of both medications. Option D is incorrect because a combined oral contraceptive pill does not provide emergency contraception and fails to meet her request for a method she does not have to remember daily.

Although menstrual changes are common during the menopausal transition, periods occurring every 14 days with heavy soaking bleeding are abnormal and require thorough investigation. This 49-year-old female has an elevated BMI, significantly increasing her risk for endometrial hyperplasia or cancer due to unopposed peripheral estrogen production. Therefore, an endometrial biopsy is the primary diagnostic step. Option A is incorrect because prescribing hormones without ruling out malignancy is unsafe. Option C is incorrect as FSH does not evaluate the source of the heavy bleeding. Option D falsely normalizes a potentially dangerous clinical presentation.

Oral levonorgestrel has significantly decreased efficacy in patients with an elevated BMI and is not recommended as first-line emergency contraception for this population. The copper intrauterine device is the most effective emergency contraceptive available, is not impacted by body weight, and provides excellent ongoing long-acting reversible contraception. Combined oral pills and depot injections do not function as post-coital emergency contraception.

Propranolol is a beta-blocker with a long history of safety and is the preferred preventive therapy for women planning pregnancy. Divalproex carries a high risk of neural tube defects and is contraindicated. Topiramate is associated with an increased risk of oral clefts. Candesartan, an angiotensin receptor blocker, is strictly contraindicated due to the severe risk of fetal renal toxicity and oligohydramnios.

When establishing a plan of care for menopause, systemic hormone replacement therapy is the most effective treatment for severe hot flashes. Because this patient has an intact uterus, she must receive a progestin in combination with estrogen to prevent endometrial hyperplasia and the associated risk of endometrial cancer. Option B is the correct choice as it provides both essential hormones. Option A is incorrect because prescribing unopposed estrogen to a woman with a uterus significantly increases her risk of developing endometrial malignancy. Option C is incorrect because local vaginal estrogen effectively treats genitourinary symptoms but does not achieve high enough systemic levels to relieve severe vasomotor symptoms. Option D is a valid non-hormonal alternative, but since she has no contraindications to hormones, systemic estrogen-progestin therapy remains the gold standard and first-line treatment for her disruptive symptoms.

A history of unprovoked deep vein thrombosis is an absolute contraindication to systemic hormone replacement therapy. Because this patient is experiencing severe and disruptive symptoms the best approach is to explore her willingness to use non-hormonal prescription medication such as selective serotonin reuptake inhibitors or gabapentin which are highly effective for hot flashes. Asking about oral estrogen therapy is incorrect because it poses a severe safety risk given her clotting history. Inquiring about dietary soy products might be helpful for mild symptoms but is generally insufficient for severe disruption. Assessing her response to topical vaginal estrogen is not relevant here because topical formulations treat genitourinary syndrome of menopause rather than systemic vasomotor symptoms. Guiding the conversation toward safe evidence based alternatives is essential for this patient.

Systemic and topical hormone replacement therapies are generally contraindicated in patients with a history of estrogen-receptor positive breast cancer. For this patient experiencing severe hot flashes, non-hormonal medications such as an oral serotonin norepinephrine reuptake inhibitor (SNRI) like venlafaxine are the safest and most effective evidence-based alternative, making Option B the correct choice. Options A and C are incorrect because both transdermal and oral estrogens carry a significant risk of stimulating residual estrogen-dependent cancer cells. Option D is incorrect because compounded bioidentical hormones still contain active estrogens and carry the exact same oncologic risks as conventional hormone therapy, despite often being marketed as a safer alternative. Additionally, an SNRI is preferred over certain SSRIs like paroxetine, which can inhibit the CYP2D6 enzyme and dangerously reduce the clinical efficacy of her concurrent tamoxifen therapy.

This patient is experiencing secondary amenorrhea accompanied by clinical signs of hyperandrogenism, specifically severe acne and hirsutism. These findings are the hallmark features of a polycystic ovary endocrine syndrome, which is a leading cause of secondary amenorrhea in adolescents following the exclusion of pregnancy. A functional hypothalamic amenorrhea disorder typically occurs in the setting of extreme stress, weight loss, or exercise, and does not cause androgen excess. A premature ovarian insufficiency syndrome presents with elevated gonadotropins and symptoms of estrogen deficiency, not hyperandrogenism. A pituitary prolactinoma secreting adenoma can cause secondary amenorrhea and galactorrhea by suppressing the hypothalamic-pituitary-ovarian axis, but it does not directly produce the virilizing signs seen in this patient during a routine clinical assessment.

Traditional norethindrone progestin-only pills have a very narrow efficacy window and must be taken within a strict three-hour timeframe. Because she missed her dose by five hours, her cervical mucus will begin to thin, significantly reducing contraceptive efficacy. She must take the late pill immediately, resume her normal schedule, and use backup barrier contraception for the next 48 hours. Emergency contraception is not indicated because unprotected intercourse has not yet occurred. Taking two pills is the protocol for missed combined oral contraceptives, not progestin-only formulations.

For patients experiencing bothersome unscheduled bleeding with an etonogestrel implant, prescribing a short course of combined oral contraceptives or a scheduled course of NSAIDs is the first-line evidence-based intervention. Removing the device is premature unless medical management fails or the patient explicitly requests discontinuation. Ordering a pelvic ultrasound is unnecessary for expected pharmacological side effects in a young patient without other red flags. Advising her to stop analgesics is incorrect, as NSAIDs actually help reduce implant-related bleeding.

Estrogen alone in a patient with an intact uterus significantly increases the risk of endometrial hyperplasia and cancer. Therefore, a progestin must be added to systemic estrogen therapy. Option A is incorrect because unopposed estrogen is contraindicated. Option C is incorrect because vaginal estrogen only treats genitourinary symptoms, not the severe vasomotor symptoms described. Option D is a non-hormonal alternative, which is not the first-line choice when the patient desires and has no absolute contraindications to hormone replacement therapy.